Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Three Times Weekly Symptom Screening for Children With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04275102
Recruitment Status : Recruiting
First Posted : February 19, 2020
Last Update Posted : February 8, 2021
Sponsor:
Information provided by (Responsible Party):
Lillian Sung, The Hospital for Sick Children

Brief Summary:
This study will evaluate the feasibility of three times weekly symptom reporting by children using the SPARK platform for 8 weeks. SPARK is a web-based application that promotes symptom screening for children receiving cancer therapies and enables access to clinical practice guidelines for symptom management. Newly diagnosed and relapsed patients with cancer will be enrolled. Children will be prompted to complete symptom screening three times weekly via SPARK with corresponding feedback sent to their healthcare providers with each completed assessment. Symptom reports will contain links to clinical practice guidelines for symptom management. Active intervention will last for 8 weeks starting from the date of enrollment.

Condition or disease Intervention/treatment Phase
Cancer Relapsed Cancer Other: SPARK Not Applicable

Detailed Description:

Primary objective is to determine the feasibility of three times weekly symptom reporting by guardians and children using the SPARK platform for 8 weeks. Feasibility will be evaluated by compliance with symptom screening and the investigators anticipate that at least 75% can achieve compliance with at least 60% of symptom evaluations.

Newly diagnosed and relapsed patients with cancer 8-18 years of age will be enrolled Children will be prompted to complete symptom screening three times weekly via SPARK with corresponding feedback sent to their healthcare providers with each completed assessment. Symptom reports will contain links to clinical practice guidelines for symptom management. Active intervention will last for 8 weeks starting from the date of enrollment.

Patient-reported outcomes will be obtained at baseline, and weeks 4, and 8. These outcomes will include the Symptom Screening in Pediatrics Tool (SSPedi), Fatigue will be measured using PROMIS, and the Pediatric Quality of Life Inventory (PedsQL) 3.0 Acute Cancer Module. Data from health records will be abstracted for all enrolled participants to evaluate symptom documentation and intervention provision at times symptom screening is completed as well as emergency room visits, clinic visits and hospitalizations.

Analyses are descriptive. The investigators' primary outcome is feasibility, sample size justification will focus on having sufficient number of guardians and children to optimize study processes and to describe the number of completed symptom assessments. The investigators will enroll up to 20-30 children, it is anticipated the investigators can enroll this number over one year. The 95% confidence intervals assuming 60% compliance will be 36-81% and 41-77% for 20 and 30 participants respectively; this precision is adequate for our purposes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Feasibility Study of Three Times Weekly Symptom Screening for Children With Cancer
Actual Study Start Date : January 24, 2020
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Experimental: Three times weekly symptom screening
Three times weekly symptom reporting by guardians and children using the SPARK platform for 8 weeks
Other: SPARK
Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.




Primary Outcome Measures :
  1. Feasibility of three times weekly symptom reporting by children using the SPARK platform for 8 weeks. [ Time Frame: 8 weeks ]
    The primary endpoint is feasibility, defined as at least 75% achieving compliance with at least 60% of symptom evaluations among guardian and self-report populations separately.


Secondary Outcome Measures :
  1. Symptom burden as measured by the total SSPedi score Total SSPedi symptom scores [ Time Frame: Baseline and weeks 4, and 8 ]
    Total SSPedi symptom which is the sum of each of the 15 SSPedi item's Likert scores, resulting in a total score that ranges from 0 (no bothersome symptoms) to 60 (worst bothersome symptoms). The recall period is yesterday or today (SSPedi).

  2. QoL will be measured using the PedsQL 3.0 Acute Cancer Module [ Time Frame: Baseline and weeks 4, and 8 ]
    Quality of life will be measured using the Pediatric Quality of Life Inventory (PedsQL) 3.0 Acute Cancer Module. The minimum value on the scale is 0 and maximum value is 100. PedsQL uses reverse scoring thus a higher score indicates a better outcome.

  3. Symptom documentation [ Time Frame: Baseline and weeks 4, and 8 ]
    Symptom documentation and intervention provision at each time point in which symptom assessment is performed will be abstracted from the health record.

  4. Number of Patients' Emergency Department Visits, Unplanned Clinic Visits and Hospitalizations over the 12-week intervention [ Time Frame: Baseline and weeks 4, and 8 ]
    The number of emergency department visits and unplanned clinic visits and hospitalizations over the 12-week intervention period will be abstracted from the health record.

  5. Fatigue [ Time Frame: Baseline and weeks 4, and 8 ]
    Fatigue will be measured using PROMIS. The recall period is the last 7 days. It is reliable and valid in children 5-18 years of age with cancer



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cancer diagnosis
  • 8-18 years of age at enrollment
  • Child has received or a plan for any chemotherapy, radiotherapy or surgery
  • Understands English or Spanish

Exclusion Criteria:

  • Cognitive disability
  • Visual impairment (cannot see SPARK even with corrective lens)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04275102


Contacts
Layout table for location contacts
Contact: Dr. Lillian Sung 4168135287 lillian.sung@sickkids.ca

Locations
Layout table for location information
Canada, Ontario
The Hospital for Sick Children Recruiting
Toronto, Ontario, Canada, M5G1X8
Sponsors and Collaborators
The Hospital for Sick Children
Investigators
Layout table for investigator information
Principal Investigator: Lillian Sung, MD, PhD The Hospital for Sick Children
  Study Documents (Full-Text)

Documents provided by Lillian Sung, The Hospital for Sick Children:
Study Protocol  [PDF] September 26, 2019

Layout table for additonal information
Responsible Party: Lillian Sung, Principal Investigator, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT04275102    
Other Study ID Numbers: REB# 1000063548
First Posted: February 19, 2020    Key Record Dates
Last Update Posted: February 8, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No